Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Treatment of diabetic foot wounds with cold plasma plaster.

- candidate number21784
- NTR NumberNTR5090
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR11-mrt-2015
- Secondary IDsVU University Medical Center 2001440
- Public TitleTreatment of diabetic foot wounds with cold plasma plaster.
- Scientific TitleCold Atmospheric Pressure Plasma as a Novel Treatment Modality in Diabetic Foot Ulcers: a Pilot Study.
- ACRONYMCold Plasma in Diabetic Foot Ulcers.
- hypothesisWe hypothesise that CAP is a safe treatment that reduces bacterial load on the wound surface and promotes wound healing.
- Healt Condition(s) or Problem(s) studiedFresh frozen plasma, Diabetic foot, Ulcers, Adults
- Inclusion criteria- Type 1 or 2 diabetes mellitus
- Foot ulcer with a maximum depth of 5 millimeters, with or without peripheral vascular disease, without evidence of bone or joint tissue in the wound base, without overt clinical infection (University of Texas Wound Classification A1, A2, C1 or C2) [17]
- Able and willing to comply with the research protocol.
- Exclusion criteria- Implanted electrical medical devices such cardiac pacemakers
- Life-threatening cardiac conductivity abnormality
- Active malignancy
- Pregnant or lactating women
- Women of childbearing age not using contraceptive measures
- A foot infection needing antibiotic treatment
- Patients with deep wounds (> 5 millimeters) or with bone or joint tissue in the wound base.
- mec approval receivedno
- multicenter trialno
- randomisedno
- groupFactorial
- TypeSingle arm
- Studytypeintervention
- planned startdate 18-apr-2016
- planned closingdate1-jul-2016
- Target number of participants20
- Interventions20 patients with foot ulcers will be treated on an outpatient basis with daily CAP for 10 days in 2 weeks. Bacterial load will be measured by culture and molecular technique of deep tissue swab at days 1, 7 and 14, and directly before and after CAP application. Standard protocols for wound treatment will be deployed, including proper offloading.
- Primary outcomeSafety of CAP treatment in diabetic foot ulcers. CAP treatment is considered safe when in ≤ 10% serious adverse advents other than infection occur, and if ≤ 60% of patients have infection.
- Secondary outcome• The effect of CAP treatment on bacterial load is considered clinically significant if bacterial load is reduced with 50% at day 14 compared to day 1 as measured by deep tissue swab, and 50% reduction in bacterial load before and directly after cold plasma plaster treatment on day 1, 7 and 14.
• Healing of the wound, defined as full epithelialization, at 2 and 12 weeks after start of treatment.
• Occurrence of clinically defined infection according to the International Working Group on the Diabetic Foot/Infectious Diseases Society of America’s classification [15,16] during treatment and after treatment.
• Clinical outcome (amputation, death, wound healing, treatment with antibiotics) 3 months after enrolment.
• Quality of life 3 months after enrolment measured with questionnaires (PAID-NL, SF-36, USER-P).
- Timepoints1-7-2015 inclusion patients 1-10.
1-11-2015 intermediate evaluation.
1-12-2015 inclusion patients 11-20.
1-4-2016 evaluation.
- Trial web sitenot applicable
- statusopen: patient inclusion
- Sponsor/Initiator VU University Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Diabetes Fonds
- Publications
- Brief summaryPlasma medicine is an innovative field of research with a high potential but with little clinical evidence to its support. Cold atmospheric plasma (CAP) devices generate an ionized gas with a cocktail of highly reactive species and UV light. They can be used for application on living tissue because these operate at normal ambient air pressure and temperature¹²³. CAP treatment has advantages over antiseptic or antimicrobial infection prevention and control, e.g. efficient, painless, instant disinfection without chance of developing antimicrobial resistance, but with stimulation of fibroblast proliferation and migration contributing to wound healing. Current evidence for CAP consists of in-vitro studies, animal studies, and studies in patient groups such as those with burn wounds. Our novel type of CAP device⁴ is simple to use and can be applied by a podiatrist and even at a patient’s home. This is a pilot study to safety and efficacy of the technology.
- Main changes (audit trail)
- RECORD11-mrt-2015 - 23-aug-2018

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar